Back to results
US 2024/0002851 A1Published application
Linkage modified oligomeric compounds and uses thereof
AssigneeIonis Pharmaceuticals, Inc.
InventorsBrooke A. Anderson, Xue-Hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
Life of this patent
Estimating the term…
Abstract
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.
Claims22
-30. (canceled)
An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides linked through internucleoside linking groups, wherein:
- at least one nucleoside comprises a modified sugar moiety;
- the modified oligonucleotide comprises a deoxy region consisting of 6-11 linked nucleosides wherein each nucleoside of the deoxy region is a stereo-standard DNA nucleoside;
- and
- at least one of the internucleoside linking groups of the modified oligonucleotide has Formula XVII:
- wherein independently for each internucleoside linking group having Formula XVII:
- X is selected from O or S;
- R1 is selected from H, C1-C6 alkyl, and substituted C1-C6 alkyl;
- and
- T is SO2R2, wherein R2 is selected from an aryl, a substituted aryl, a heterocycle, a substituted heterocycle, an aromatic heterocycle, a substituted aromatic heterocycle, a diazole, a substituted diazole, a C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, substituted C1-C6 alkyl, substituted C1-C6 alkenyl substituted C1-C6 alkynyl, and a conjugate group.
6 more elements
Dependencies are inferred from the claim text.